Medical Properties Trust (MPW)
(Real Time Quote from BATS)
$4.77 USD
-0.08 (-1.65%)
Updated Jun 17, 2024 10:44 AM ET
5-Strong Sell of 5 5
C Value C Growth D Momentum C VGM
Medical Properties (MPW) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.17 | $7.00 | $4.00 | 6.60% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Medical Properties comes to $5.17. The forecasts range from a low of $4.00 to a high of $7.00. The average price target represents an increase of 6.6% from the last closing price of $4.85.
Analyst Price Targets (9 )
Broker Rating
Medical Properties currently has an average brokerage recommendation (ABR) of 3.42 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 3.42 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, one is Strong Buy, representing 8.33% of all recommendations. A month ago, Strong Buy represented 8.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/MPW.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 2 |
Buy | 0 | 0 | 0 | 1 | 2 |
Hold | 7 | 7 | 7 | 6 | 4 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 3 | 3 | 3 | 3 | 4 |
ABR | 3.42 | 3.42 | 3.42 | 3.33 | 3.23 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/10/2024 | Colliers Securities | Barry Oxford | Moderate Buy | Hold |
4/8/2024 | Truist Securities | Michael Lewis | Hold | Hold |
3/1/2024 | Exane BNP Paribas | Nathan D Crossett | Hold | Strong Buy |
2/29/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
1/5/2024 | KeyBanc Capital Markets | Austin Wurschmidt | Strong Buy | Hold |
1/3/2024 | Mizuho SecuritiesUSA | Vikram Malhotra | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.42 |
ABR (Last week) | 3.42 |
# of Recs in ABR | 12 |
Average Target Price | $5.17 |
LT Growth Rate | 8.00% |
Industry | REIT and Equity Trust - Other |
Industry Rank by ABR | 177 of 252 |
Current Quarter EPS Est: | 0.21 |